---
document_datetime: 2024-10-28 10:54:16
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/nubeqa-epar-all-authorised-presentations_en.pdf
document_name: nubeqa-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.704737
conversion_datetime: 2025-12-29 20:27:18.938155
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical form   | Route of administration   | Immediate packaging   | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|-----------------------|-------------|
| EU/1/20/1432/001 | NUBEQA            | 300 mg     | Film-coated tablet    | Oral use                  | blister (PVC/alu)     | 112 tablets |